Partnerships are key for rare disease drug discovery and development

April 11, 2017 Christoph Graener

What kinds of partnerships are key to getting rare disease research out of the lab and to patients as therapies and cures? Wendy White, Board Chairman of Global Genes, discusses her work on behalf of the leading global rare disease patient advocacy organization, and the impact patient advocacy groups are making on rare disease research.

Interviewer: Erin Righetti – Senior Manager, Content Marketing and Communications, EBD Group
Interviewee: Wendy White – Chair, Global Genes

Previous Article
Newron CEO on Xadago and upcoming pipeline milestones

CEO of Newron, Stefan Weber, joined Scrip to discuss the company's recently approved Parkinson's therapy Xa...

Next Article
Prexton CEO on future for novel Parkinson’s therapy

Francois Conquet, CEO of Prexton Therapeutics, a biotech focused on central nervous system disorders, discu...